Cancer Family
Secondary Malignant Neoplasm
CI-CAN-00000346SMNExplore in graph →
4,275 active trials56 approved drugs532 evidence items
- NCIt
- C4968
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000346SMNExplore in graph →
Clinical trials
14,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,961)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04158947 | A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone(HER2BAT) | unknown | Phase 2 | 130 | xuexin heOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT04380103 | A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 106 | Chinese Academy of Medical SciencesOTHER | 1 | May 8, 2020 |
| clinicaltrials |
| NCT04363255 | First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC | unknown | Phase 2 | 20 | Taizhou HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT03592706 | Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy | unknown | Phase 2 / Phase 3 | 60 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT04131621 | Nivolumab/Ipilimumab in Second Line CUP-syndrome(CheCUP) | unknown | Phase 2 | 194 | University Hospital HeidelbergOTHER | 1 | Apr 15, 2020 | clinicaltrials |
| NCT04080154 | Study of Anlotinib After Lenvatinib in Patients With Hepatocellular Carcinoma(ALTER-H-002) | unknown | Phase 2 | 28 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT04029428 | Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression(POLNETS_PRRT) | unknown | Phase 2 | 150 | University of Warmia and MazuryOTHER | 1 | Apr 1, 2020 | clinicaltrials |
| NCT02161822 | Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients | unknown | Phase 2 | 60 | Samsung Medical CenterOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT03823625 | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)(SQUINT) | unknown | Phase 2 | 112 | Fondazione Ricerca TraslazionaleOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT04319484 | Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus(LLTHVV) | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Mar 24, 2020 | clinicaltrials |
| NCT04314297 | Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study | unknown | Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Mar 19, 2020 | clinicaltrials |
| NCT02123381 | Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 100 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT04296747 | Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer | unknown | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 0 | Mar 5, 2020 | clinicaltrials |
| NCT03585998 | Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer | unknown | Phase 2 | 51 | Samsung Medical CenterOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT02583542 | A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers(TORCMEK) | unknown | Phase 1 / Phase 2 | 118 | Queen Mary University of LondonOTHER | 1 | Feb 25, 2020 | clinicaltrials |
| NCT04273100 | PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC(PLTHCC) | unknown | Phase 2 | 56 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03834233 | Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma(CA209-9JC) | unknown | Phase 2 | 24 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT03603756 | SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | unknown | Phase 2 | 45 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT04263870 | Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(CTSCAPOXSEA) | unknown | Phase 2 | 36 | Sichuan UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03422029 | Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients | unknown | Phase 2 | 20 | Peking UniversityOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT04261465 | NUVOLA TRIAL Open-label Multicentre Study(NUVOLA) | unknown | Phase 2 | 35 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03613597 | Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer | unknown | Phase 2 | 118 | Guizhou Medical UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03613753 | Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 72 | ShengFa SuOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03913182 | Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer | unknown | Phase 2 | 39 | Shanghai Chest HospitalOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04254471 | This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients | unknown | Phase 2 / Phase 3 | 313 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04241523 | Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04236310 | A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. | unknown | Phase 2 | 37 | Ruijin HospitalOTHER | 0 | Jan 22, 2020 | clinicaltrials |
| NCT04229849 | Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 164 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 18, 2020 | clinicaltrials |
| NCT04227808 | Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular Carcinoma | unknown | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04222543 | Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging(PIVOT) | unknown | Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT04193696 | RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC) | unknown | Phase 2 | 39 | Guangxi Medical UniversityOTHER | 0 | Jan 9, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04192682 | Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 40 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT04213898 | SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer | unknown | Phase 1 / Phase 2 | 39 | Henan Cancer HospitalOTHER_GOV | 0 | Dec 30, 2019 | clinicaltrials |
| NCT04213937 | Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 386 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04006041 | Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer | unknown | Phase 2 | 44 | Jianhua FuOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT04204577 | The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | unknown | Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 19, 2019 | clinicaltrials |
| NCT03985670 | Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer | unknown | Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 12, 2019 | clinicaltrials |
| NCT04146181 | Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 103 | Sinocelltech Ltd.INDUSTRY | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04190745 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | unknown | Phase 2 | 116 | Zhejiang Cancer HospitalOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04157140 | Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC | unknown | Phase 2 | 48 | Jinglong ChenOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT03700359 | A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC | unknown | Phase 2 | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 29, 2019 | clinicaltrials |
| NCT04168944 | Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 108 | RenJi HospitalOTHER | 0 | Nov 19, 2019 | clinicaltrials |
| NCT04169399 | Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT04164238 | Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients | unknown | Phase 2 | 90 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT04162158 | Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 200 | Beijing 302 HospitalOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT04156958 | Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma(FSTAMBTA) | unknown | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT04148898 | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis(OWONBNSCLCLM) | unknown | Phase 2 | 80 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03825705 | A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2020source: clinicaltrials